Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

An AI-powered imaging tool developed by Brainomix has been used to enrich data from a phase 2a trial of Endeavor BioMedicines ...

The FDA has started a priority review of AstraZeneca's IL-33-targeting antibody tozorakimab for chronic obstructive pulmonary ...

Every few years, drug development goes through a moment where a new technology promises to change everything. Artificial ...

At present, the only FDA-approved oral therapies for HAE are BioCryst's Orladeyo (berotralstat) and KalVista Pharma's Ekterly ...

Speaking to investors and analysts at its capital markets day in London, UK, Sandoz presented its new strategy – Bio100 – ...

Registration and the full programme are available on the DIA-MHRA Global Summit page. Follow the conversation at ...

An NHS trust in the UK has become the first site in Europe to offer Roche's experimental drug trontinemab to patients ...

Hard on the heels of a big disappointment in its cardiovascular pipeline, Novartis has suffered another – this time for its ...